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ABSTRACT
Cytochrome P450 (CYP) 1A1 is a phase I enzyme that can activate various 
compounds into reactive forms and thus, may contribute to carcinogenesis. In this 
study, we investigated the expression, methylation status, and functional role of 
CYP1A1 on prostate cancer cells. Increased expression of CYP1A1 was observed 
in all cancer lines (PC-3, LNCaP, and DU145) compared to BPH-1 (P < 0.05); and 
was enhanced further by 5-aza-2’-deoxycytidine treatment (P < 0.01). Methylation-
specific PCR (MSP) and sequencing of bisulfite-modified DNA of the xenobiotic 
response element (XRE) enhancer site XRE-1383 indicated promoter methylation 
as a regulator of CYP1A1 expression. In tissue, microarrays showed higher 
immunostaining of CYP1A1 in prostate cancer than normal and benign prostatic 
hyperplasia (BPH; P < 0.001), and methylation analyses in clinical specimens 
revealed significantly lower methylation levels in cancer compared to BPH at all 
enhancer sites analyzed (XRE-1383, XRE-983, XRE-895; P < 0.01). Interestingly, 
smoking affected the XRE-1383 site where the methylation level was much lower in 
cancer tissues from smokers than non-smokers (P < 0.05). CYP1A1 levels are thus 
increased in prostate cancer and to determine the functional effect of CYP1A1 on 
cells, we depleted the gene in LNCaP and DU145 by siRNA. We observe that CYP1A1 
knockdown decreased cell proliferation (P < 0.05) and increased apoptosis (P < 0.01) 
in both cell lines. We analyzed genes affected by CYP1A1 silencing and found that 
apoptosis-related BCL2 was significantly down-regulated. This study supports an 
oncogenic role for CYP1A1 in prostate cancer via promoter hypomethylation that 
is influenced by tobacco smoking, indicating CYP1A1 to be a promising target for 
prostate cancer treatment.
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INTRODUCTION
Prostate cancer is the most frequently diagnosed 
malignancy and the second leading cause of cancer death 
among men in the United States [1]. It is estimated that 
in the year 2016, there will be 180,890 new cases and 
26,120 deaths due to prostate cancer [1]. This cancer is a 
disease of aging as 1 in 325 persons will develop invasive 
prostate cancer prior to the age of 50, but drastically rises to 
1 in 48 for those aged 50 to 59, 1 in 17 aged 60 to 69, and 1 
in 10 aged 70 years and older [1]. Despite these high rates, 
the genetic basis of this disease is not well understood.
Recent meta-analysis showed a close association 
between several cytochrome P450 (CYP) 1A1 
polymorphisms and prostate cancer risk [2, 3], suggesting 
that CYP1A1 may contribute to prostate cancer 
tumorigenesis. The carcinogenic potential of CYP1A1 
is thought to be associated with metabolic activation of 
procarcinogens such as polycyclic aromatic hydrocarbons 
(PAHs), which can form PAH-DNA adducts in several 
types of malignancies [4, 5]. Although PAHs produce 
significant levels of PAH-DNA adducts in prostate 
cancer cells, its correlation with prostate cancer risk is 
controversial [6, 7]. Interestingly, recent studies have 
shown that CYP1A1 promotes breast cancer progression 
even in the absence of xenobiotics [8] and suggests 
the possibility that this gene may be involved in other 
carcinogenic mechanisms. 
CYP1A1 is located in chromosome 15q24.1 region, 
consists of 7 exons and is roughly 6 kilobases in length. 
The protein localizes mainly to the endoplasmic reticulum 
and is composed of 512 amino acids with a size of 58 kDa. 
Under normal physiologic conditions, CYP1A1 expression 
is induced by PAHs via activation of the aryl hydrocarbon 
receptor (AhR). The AhR complex then translocates to the 
nucleus and binds to its partner protein, aryl hydrocarbon 
receptor nuclear translocator (ARNT). The AhR/ARNT 
heterodimer binds to specific DNA recognition sites 
termed xenobiotic responsive elements (XREs) located 
upstream of the transcription start site and initiates 
CYP1A1 transcription [3, 9]. Thus CYP1A1 expression is 
regulated by direct interaction between the AhR/ARNT 
heterodimer and XREs.
Studies have shown that epigenetic changes 
can regulate the expression of several tumor-specific 
genes [10, 11]. We have demonstrated that DNA 
hypermethylation of CpG islands involving the promoter 
of tumor suppressor genes can lead to functional loss of 
these genes in several types of malignancies, including 
prostate cancer [12–14]. Also, DNA hypomethylation of 
oncogenic genes is thought to be associated with prostate 
cancer development and progression [15]. Previous 
studies have shown that the expression level of CYP1A1 
is frequently up-regulated in several human tissues due 
to hypomethylation of XRE sites which may promote 
binding of the AhR/ARNT heterodimer [16–19].
One putative mechanism affecting XRE methylation 
status of CYP1A1 is tobacco smoking as demonstrated in 
human lung [17, 18]. It is widely accepted that tobacco 
smoking can cause lung cancer, and smoking-induced 
CYP1A1 gene alterations may contribute to the initiation 
of lung carcinogenesis [17, 18]. Importantly, recent studies 
have shown a close association of smoking with the risk of 
prostate cancer [20–23]. Therefore we hypothesized that 
smoking may affect CYP1A1 expression in human prostate 
tissue through the alteration of XRE CpG methylation in 
the enhancer region of this gene.
In this study, we assessed whether CYP1A1 levels 
were elevated in prostate cancer compared to normal 
prostate or benign prostatic hyperplasia (BPH) using 
tissue microarray (TMA) of human specimens as well 
as prostatic cell lines (cancer versus BPH-1). Also, 
we evaluated the methylation level of XRE sites of the 
CYP1A1 enhancer in cell lines and clinical samples and 
determined the effects of smoker status. Finally, we 
knocked the CYP1A1 gene down in prostate cancer cell 
lines by RNA interference and performed functional 
analysis to evaluate its biological role in tumorigenesis.     
RESULTS
CYP1A1 expression in prostate cell lines and 
clinical samples
Initially we measured mRNA and protein expression 
levels of CYP1A1 in 3 prostate cancer cell lines (PC-3, 
LNCaP and DU145) and as a comparison, measured 
expression in BPH-1 cells. Both mRNA (Figure 1A) 
and protein (Figure 1B) were up-regulated with variable 
increases in cancerous cells with DU145 showing 
the largest elevation of expression compared with 
nonmalignant BPH-1 cells. Next we investigated the 
expression of CYP1A1 by immunohistochemical staining 
in 102 primary prostate cancers, 14 normal prostate and 
70 BPH samples obtained from TMAs. While CYP1A1 
expression was weak or not detected in most of the normal 
prostate (0.79 ± 0.11) and BPH (0.57 ± 0.07) tissues, the 
majority of prostate cancer samples showed much higher 
CYP1A1 immunoreactivity with an average staining score 
of 1.82 ± 0.08 (P < 0.001, Figure 1C). Thus CYP1A1 is 
up-regulated in prostate cancer cell lines and tissues.
Increased expression of CYP1A1 in prostate 
cancer cell lines after 5-aza-dC treatment
We utilized 5-aza-deoxycytidine (5-aza-dC) to 
screen the methylation status of CYP1A1 in prostate 
cancer cell lines. As shown in Figure 2A, CYP1A1 mRNA 
expression was markedly increased in all cancer cells 
after treatment indicating that promoter CpG methylation 
affects CYP1A1 expression. To validate the relationship 
between CpG methylation and expression of the CYP1A1 
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transcript, we performed methylation-specific PCR (MSP) 
analysis of region A (MSP-A) of the enhancer region 
which contains the XRE-1383 site (see Figure 6A, 6B) 
using bisulfite-modified DNA of treatment groups. In 
control cells, densitometry measurements of MSP-A and 
USP-A bands show higher levels of methylation in all 
cancer lines with PC-3 having 100% (Figure 2B). Bisulfite 
DNA sequencing confirmed that most CpG sites in region 
A area were completely methylated in untreated PC-3 cells 
(Figure 2B). After 5-aza-dC treatment however, a dramatic 
reduction in % methylation of this site were observed in 
all cancer lines. These results show that expression of 
Figure 1: CYP1A1 expression in prostate cancer cell lines and tissues. (A) Relative mRNA expression levels of CYP1A1 in 
prostate cancer cell lines (PC-3, LNCaP, and DU145) and benign cells (BPH-1) as measured by real-time PCR. The expression level of 
CYP1A1 mRNA was significantly up-regulated in prostate cancer cell lines. Experiments done in triplicate; *P < 0.05, ***P < 0.001. 
(B) Representative immunoblot displaying CYP1A1 (top gel) and GAPDH (bottom gel) in BPH-1, PC-3, LNCaP and DU145. 
(C) Representative immunostaining of CYP1A1 in clinical samples (normal prostate, benign prostatic hyperplasia (BPH), and prostate 
cancer (PC) obtained from tissue microarray. Bar graph: CYP1A1 protein expression in prostate cancer (n = 102) samples was significantly 
higher than that of normal (n = 14) or BPH (n = 70) tissues. ***P < 0.001.
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CYP1A1 is inversely regulated by methylation of region 
A of the promoter in human prostate cancer cell lines.
Methylation level of the CYP1A1 enhancers in 
prostate tissues
Since Figure 1C indicated increased expression of 
CYP1A1 in prostate cancer regions, we then determined 
whether cancer tissues also have lower methylation levels. 
MSP of region A in 176 prostate cancer and 69 BPH 
samples were analyzed. Representative MSP-A and 
USP-A bands of 24 BPH and 24 prostate cancer tissues are 
shown in Figure 2C. The relative methylation amount of 
the CYP1A1 promoter in region A was significantly lower 
in prostate cancer (49.2 ± 1.6%) than in BPH samples 
(62.5 ± 1.3%; P < 0.01). Also, bisulfite DNA sequencing 
was performed to confirm whether the MSP bands reflect 
the true methylation status of the CYP1A1 enhancer. 
Representative sequence chromatograms of two BPH 
and two prostate cancer samples in region A are shown 
in Figure 2D and methylation of the XRE-1383 site was 
generally higher in BPH than in prostate cancer tissues. 
These results indicate that methylation analysis by MSP 
was consistent with bisulfite DNA sequencing.
MSP analysis of other CYP1A1 enhancers 
containing XRE-983 (region B) and XRE-895 (region 
C) (see Figure 6A, 6B) was also performed. As shown in 
Figure 3A, most BPH tissues showed both MSP-B and 
USP-B bands whereas many prostate cancer tissues had 
only a USP-B band. The relative methylation level of 
CYP1A1 in region B was significantly lower in prostate 
cancer (18.5 ± 2.1%) than BPH samples (32.1 ± 2.0%; 
P < 0.001). Likewise, prostate cancer tissues have lower 
CYP1A1 methylation in region C in comparison with 
BPH samples (18.0 ± 2.3% and 40.7 ± 4.2%, respectively; 
P < 0.001, Figure 3B). Therefore DNA hypomethylation 
of three CYP1A1 XRE sites was more common in prostate 
cancer than BPH tissues. We further evaluated the 
relationship between the methylation level of the CYP1A1 
enhancer and pathological status; however, no significant 
association was found for either grade or stage of cancer 
(data not shown).
Methylation of CYP1A1 enhancers in smoker 
and non-smoker prostate cancer tissues
We then evaluated the association between smoker 
status and the methylation level of CYP1A1 enhancers in 
prostate cancer patients. Of 176 patients who underwent 
radical prostatectomy, 78 never smoked, 30 were ex-
smokers who had quit smoking 7 or more days before 
surgery, 45 were current smokers, and the remaining 
23 were unknown. A past history of smoking was not 
significantly associated with the methylation level in 
each region (data not shown). Interestingly however, the 
methylation level of CYP1A1 in the region A site was 
significantly higher in 108 nonsmokers (never smokers 
and ex-smokers for > 7 days combined) than 45 smokers 
(52.2 ± 2.1% and 44.6 ± 2.9%, respectively; P < 0.05, 
Figure 3C). Cohen’s d value for this difference is calculated 
to be 0.36 which is moderate. No differences were found 
in regions B and C. Thus tobacco smoking may affect the 
methylation of the CYP1A1 enhancer region A.
Effect of CYP1A1 knockdown on prostate cancer 
cell growth
The higher basal expression levels of CYP1A1 in 
prostate cancer tissues led us to examine the functional 
significance of CYP1A1 in prostate cancer. We determined 
this by testing the effects of CYP1A1 reduction on 
prostate cancer cell viability. LNCaP and DU145 were 
selected as these showed higher constitutive levels of 
CYP1A1 (Figure 1A and 1B). After transfection with 
two different CYP1A1 siRNAs (#1 and #2), significant 
reduction of CYP1A1 mRNA was found in both LNCaP 
and DU145 cells (Figure 4A). CYP1A1 protein was also 
lowered as well (see Figure 5C). As shown in Figure 4B, 
knockdown of CYP1A1 caused the growth of these cells 
to be significantly inhibited in a time-dependent manner as 
compared with controls. 
Effect of CYP1A1 knockdown on apoptosis
Since attenuation of CYP1A1 significantly inhibited 
proliferation of prostate cancer cell lines, we hypothesized 
that this may be due to apoptosis induction. Apoptosis 
was examined in control siRNA and CYP1A1 siRNA#2-
treated cells and results for LNCaP and DU145 cells at 
48 hours post-transfection are shown in Figure 5A. In 
both cell lines, the apoptotic and early apoptotic fractions 
(upper right and lower right quadrants, respectively) were 
significantly greater in CYP1A1-depleted cells compared 
to control cells. Similar results were also observed in 
both LNCaP and DU145 cells at 72 hours after siRNA 
transfection (data not shown). This supports an anti-
apoptotic role for CYP1A1 suggesting that it regulates 
tumorigenicity by affecting the apoptotic pathway. 
To further understand the precise mechanism of 
the pro-apoptotic effect on prostate cancer cells induced 
by CYP1A1 knockdown, we performed array analyses 
to determine which apoptotic genes are altered due to 
CYP1A1 in LNCaP cells. There were 3 genes up-regulated 
and 2 genes down-regulated two-fold or greater after 
CYP1A1 depletion (Supplementary Table S1). Among 
these 5 genes, only BCL2 was found to be significantly 
altered in both LNCaP and DU145 cells by real-time 
PCR using Taqman probes (Figure 5B). Also, BCL2 
protein levels were significantly decreased in CYP1A1 
siRNA#2-treated cells compared with control in both cell 
lines (Figure 5C). These data indicate that attenuation of 
CYP1A1 expression caused reduction of BCL2 expression 
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with increased apoptotic effects in prostate cancer. 
Furthermore, we sought to determine whether CYP1A1 
knockdown inhibits AKT phosphorylation since a recent 
study showed that CYP1A1 is associated with the PI3K-
AKT signaling pathway in breast cancer cell lines [8]. As 
shown in Figure 5C, CYP1A1 knockdown reduced AKT 
Figure 2: Analysis of CYP1A1 methylation in region A (XRE-1383). (A) CYP1A1 expression before and after demethylation 
(5-aza-dC) treatment in human prostate cancer cell lines as measured by real-time PCR. CYP1A1 mRNA expression was significantly 
increased after 5-aza-dC treatment as compared with that before demethylation in PC-3, LNCaP, and DU145. Experiments done in 
triplicate; **P < 0.01, ***P < 0.001. (B) After 5-aza-dC treatment and performing methylation-specific PCR (MSP) on bisulfite-modified 
DNA, densitometry of MSP-A and USP-A bands were measured using Image J software and methylation calculated as MSP/[MSP+USP]. 
The amount of methylation dramatically decreased in all prostate cancer cell lines compared with untreated controls. Chromatogram: 
DNA sequencing shows CpG sites around region A were completely methylated in PC-3 cells. (C) Representative results of MSP-A and 
USP-A of CYP1A1 enhancer in benign prostate hyperplasia (BPH) and prostate cancer (PC) samples. Bisulfite-modified DNA of clinical 
specimens underwent MSP. Top and bottom gels show MSP-A and USP-A bands, respectively. Each column is samples from the same 
patient. Bar graph: Methylation of CYP1A1 was significantly lower in prostate cancer (PC, n = 176) than BPH (n = 69) samples as measured 
by densitometry of gel bands. **P < 0.01. (D) Typical bisulfite DNA sequencing chromatograms in BPH and prostate cancer (PC) samples. 
Though the region A site was partially methylated in samples, methylation was more prominent in BPH than in prostate cancer.
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phosphorylation in both cell lines indicating CYP1A1 
may be an upstream activator of the PI3K-AKT signaling 
pathway. Figure 5D describes a proposed simplified 
schematic representation of the effect of CYP1A1 down-
regulation in prostate cancer cells.
DISCUSSION
In this study, we demonstrate that prostate 
cancer has high expression of CYP1A1 through DNA 
hypomethylation of XRE sites. It is well known that 
methylation of CpG sites within the gene promoter is 
significantly related to down-regulation or silencing 
of several types of genes. Previous studies have shown 
that the expression of human CYP1A1 gene may, at least 
in part, be regulated by methylation of the XRE core 
sequence 5′-GCGTG-3′ (or 5′-CACGC-3′) located in the 
5′-upstream region [16–19]. Our study on prostate cancer 
also supports regulation by methylation as treatment of PC-
3, LNCaP, and DU145 with demethylating agent caused an 
enhanced increase of CYP1A1 expression with dramatic 
loss of methylation as shown by MSP/USP analyses of the 
enhancer XRE-1383 site. These results are in agreement 
with Sterling and Cutroneo [24] who find CYP1A1 protein 
to be expressed constitutively in all of these cancer lines; 
and Okino et al [16]. observes LNCaP to be methylated 
Figure 3: Analysis of CYP1A1 methylation in enhancer regions B (XRE-983) and C (XRE-895), and effect of smoking 
on methylation levels. DNA of clinical specimens underwent bisulfite modification followed by methylation-specific PCR (MSP) 
analyses. (A) Representative gel results of MSP-B (top gel) and unmethylation-specific PCR (USP)-B (bottom gel) of CYP1A1 enhancer in 
benign prostate hyperplasia (BPH) and prostate cancer (PC) samples. Bar graph: The prevalence of CYP1A1 methylation was significantly 
lower in prostate cancer (n = 176) than BPH (n = 69) samples as measured by densitometry of gel bands. ***P < 0.001. (B) Representative 
gel results of MSP-C (top gel) and USP-C (bottom gel) of CYP1A1 enhancer in BPH and prostate cancer (PC) samples. Bar graph: 
A significant reduction in CYP1A1 methylation levels in prostate cancer (PC) samples were also observed for this site. ***P < 0.001. 
(C) CYP1A1 methylation levels in relation to tobacco smoker status at all 3 regions. Smoking habit affected the methylation level of 
CYP1A1 region A. Non-smokers n = 108, Smokers n = 45; *P < 0.05.
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at enhancer sites of the CYP1A1 promoter. It is worthy to 
note that despite the presence of methylation at the XRE-
1383 site, all untreated cancer cells displayed increased 
though variable constitutive levels of CYP1A1 (compared 
to BPH-1). However paradoxical, we can point out that 
PC-3 cells that showed complete methylation by MSP/
USP densitometry and bisulfite sequencing had only a 
small increase in CYP1A1 expression, whereas LNCaP 
and DU145 displayed partial methylation that can lead to 
relatively higher gene expression. Compared to LNCaP, 
it is not known why DU145 had increased CYP1A1 
expression despite elevated levels of methylation. Other 
epigenetic processes such as histone acetylation and 
deacetylation has been shown to affect gene transcription 
[25] and further studies are needed to determine if this 
could also play a role. Nonetheless, 5-aza-dC treatment 
showed a clear and pronounced inverse effect between 
expression and methylation of CYP1A1. 
In tissue, a similar pattern was also observed as 
TMA specimens displayed a significant increase of 
CYP1A1 expression in prostate cancer compared to 
normal and BPH; and methylation analyses of clinical 
specimens exhibited cancer to be hypomethylated at all 
three enhancer sites (XRE-1383, XRE-983, XRE-895) 
compared to BPH. In contrast to our results, Okino et al. 
[16] did not detect methylation in the enhancer region of 
all 30 non-cancerous prostates whereas 11 of 30 tumor 
specimens showed methylation. Reasons for discrepancy 
with our study are not known but in their study, expression 
of CYP1A1 was not measured and would be of interest 
if a correlation existed with methylation in their clinical 
specimens. In support of our results however, in other 
studies that utilized normal prostate tissues only, Martin 
et al. [26] determined that all 10 specimens were devoid 
of CYP1A1 by Western analysis and John et al. [7] 
observed minimal gene expression by real-time PCR. 
Thus taken together with our results of prostatic tissues 
and cell lines, these findings strongly suggest that DNA 
hypomethylation of the CYP1A1 enhancer is a frequent 
event in prostate cancer and involved in the induction of 
CYP1A1 expression. 
Recently several epidemiologic reports using 
relatively large cohorts suggest that tobacco smoking, an 
important risk factor for several cancers [27, 28], may also 
Figure 4: Effect of CYP1A1 knockdown on cell proliferation in prostate cancer cell lines. (A) Knockdown of CYP1A1 levels 
in LNCaP and DU145 were determined by real-time PCR at 48 hours after transfection with two different CYP1A1 siRNAs. Both siRNA’s 
significantly reduced CYP1A1 expression. Experiments done in triplicate; **P < 0.01. (B) Cell viability was analyzed by the MTS cell 
proliferation assay at 0, 24, 48 and 72 hours after siRNA treatment. In both cell lines, the attenuation of CYP1A1 significantly inhibited cell 
viability in a time dependent manner. Experiments done in triplicate; *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 5: Effect of CYP1A1 knockdown on apoptosis. (A) Apoptosis assays with LNCaP (upper graphs) and DU145 (lower 
graphs) cells were measured 48 hours post-siRNA#2 transfection by flow cytometry. Representative biparametric histograms showing 
cell populations in early (bottom right quadrant) and late (top right quadrant) apoptotic, and viable (bottom left quadrant) states for each 
treatment. Bar graph: The percentage of apoptotic cell fractions (early plus late apoptotic cells) in CYP1A1 siRNA#2 transfectants were 
significantly elevated compared to controls. Experiments done in triplicate; **P < 0.01, ***P < 0.001. (B) Verification of cDNA microarray 
data. Among 5 genes significantly altered due to siRNA#2 (see Supplementary Table S1), only BCL2 was confirmed to be down-regulated 
by real-time PCR using Taqman probe in both LNCaP and DU145. No differences in remaining genes were observed. Experiments done in 
triplicate; **P < 0.01, ***P < 0.001. (C) Immunoblotting analysis of CYP1A1, phospho AKT, total AKT and BCL2 in control and CYP1A1 
siRNA#2-transfected LNCaP and DU145 cells. GAPDH was used as a loading control. (D) Schematic representation of the proposed effect 
of CYP1A1 down-regulation in prostate cancer. CYP1A1 knockdown inhibits BCL2 expression through the inactivation of AKT, leading to 
prostate cancer cell death. 
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be associated with prostate cancer [20–23]. It is postulated 
that the induction of several carcinogen relevant genes, 
especially CYP1A1, could play important roles in smoking-
induced tumorigenesis [29, 30]. In the prostate, studies by 
Sterling and Cutroneo [24] and Hruba et al. [6] showed 
that CYP1A1 expression was enhanced by benzo[a]pyrene, 
a genotoxin in tobacco smoke. These reports led us to 
determine the possible association between smoking and 
methylation levels of the CYP1A1 enhancer in prostate 
cancer patients. Here, we clearly show for the first time 
that methylation of the CYP1A1 enhancer encompassing 
the XRE-1383 site was especially affected by smoking 
with a medium effect size difference as measured by 
Cohen’s d value; and this observation is in agreement 
with previous experiments on human lung tissues [17, 18]. 
Though we haven’t measured the correlation of CYP1A1 
Figure 6: Diagram of the CYP1A1 enhancers and locations of primers. (A) Schematic representation of 10 xenobiotic responsive 
elements (XRE) located upstream of the transcription start site. Numbers represent bp prior to start site for each XRE. DNA methylation 
levels of CYP1A1 enhancer region A (-1383 bp), B (-983 bp) and C (-895 bp) were evaluated in this study. (B) Location of designed primers 
utilized for amplification of regions A, B and C of the CYP1A1 enhancer are depicted. Methylation-specific PCR (MSP) and unmethylation-
specific PCR (USP) primers contain several CpG sites within the primer sequence whereas universal primers do not contain any CpG sites. 
Vertical arrows indicate CpG sites and large arrowheads indicate XRE core sequence.
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expression in tissue with smoker status, the evidence is 
strong to predict that CYP1A1 levels would be higher 
in smokers due to lower methylation. Thus smoking 
could influence the pathogenesis of prostate cancer via 
the epigenetic dysregulation of CYP1A1. The putative 
mechanisms underlying tobacco smoking and regulation 
of CYP1A1 methylation is that smoking promotes AhR/
ARNT heterodimer binding to XREs which leads to loss 
of methylation by eliminating DNA methyltransferases 
from the CYP1A1 enhancer [19]. Therefore tobacco smoke 
may indirectly enhance demethylation of the CYP1A1 
enhancer.
It should be noted that the expression level of many 
genes induced by smoking can be reduced after smoking 
cessation [31]. In the case of CYP1A1, a study by Anttila 
et al. [17] showed the methylation level of its promoter to 
increase within 1–7 days after quitting smoking in lung 
cancer which may inhibit the binding of AhR/ARNT 
heterodimer and subsequently lead to a reduction of 
CYP1A1 expression. In our study, ex-smokers who had 
quit smoking 7 or more days before surgery combined with 
never-smokers showed higher CYP1A1 methylation levels 
compared with current smokers, indicating smoking to be a 
modifiable risk factor for prostate cancer that is dependent 
on CYP1A1 expression. This observation can help to add to 
the recommendation for tobacco smoking cessation. 
Significant up-regulation of CYP1A1 has been 
observed in several types of malignancies, i.e. esophagus, 
breast, urinary bladder, and brain tumor, and is associated 
with poor prognosis [32–36]. These findings are 
conceivable since CYP1A1 is known to play an important 
role in the formation of PAH-DNA adducts which may 
induce mutations in several cancer-related genes that 
contribute to carcinogenesis [37, 38]. Though previous 
research has failed to demonstrate a role for PAH-DNA 
adducts as a cancer factor in the prostate [6, 7], our 
results showing that prostate cancer has high CYP1A1 
expression as compared to normal/benign prostate 
tissues suggests that CYP1A1 may contribute to prostate 
cancer pathogenesis. We observe that reduction of basal 
CYP1A1 expression leads to significant inhibition of cell 
proliferation through induction of apoptosis in prostate 
cancer cells, indicating CYP1A1 expression is critical for 
cell growth, and this is in concordance with Hruba et al. 
[6] who showed that enhanced CYP1A1 levels induced by 
benzo[a]pyrene displayed no effect on either apoptosis 
or cell cycle arrest in LNCaP cells. Interestingly, a recent 
study has also revealed that the attenuation of CYP1A1 
could prevent breast cancer progression even in the 
absence of xenobiotics [8]. Thus CYP1A1 appears to have 
both canonical carcinogen metabolic function as well as its 
own oncogenic function. 
We further identified that the effects of CYP1A1 
knockdown on increased apoptosis in prostate cancer 
cell lines were correlated with reduction of anti-
apoptotic BCL2, the primary gatekeeper of the intrinsic 
(mitochondrial) apoptotic pathway. This is expected since 
metabolites of CYP1A1 such as heterocyclic aromatic 
amines have been shown to cause increase in BCL2 mRNA 
and protein [39]. BCL2 is commonly overexpressed in 
prostate cancer compared to normal prostate [40] and 
elevation of BCL2 expression is associated with poor 
prognosis and suspected in the development of castration-
resistant prostate cancer [41–43]. Currently several 
clinical trials targeting BCL2 expression in prostate 
cancer are ongoing [44]; therefore CYP1A1 may be a 
promising target for prostate cancer treatment since it is 
closely associated with BCL2 expression. What remain 
unclear are the mechanisms of CYP1A1 regulation of 
BCL2. Expression of BCL2 is involved in the PI3K-
AKT signaling pathway implicated in the development 
and progression of prostate cancer [45–47] and indeed, 
CYP1A1 metabolites have been shown to lead to AKT 
phosphorylation [48]. AKT activated by PI3K leads to the 
activation of NFkB, which then translocates to the nucleus 
and transcribes BCL2. In this study, we show that CYP1A1 
knockdown can cause reduction of AKT phosphorylation 
in prostate cancer cells and this effect was also shown 
in breast cancer cells [8]. This inhibition of AKT could 
then promote FOXO3a and Par-4 activation leading to 
apoptosis as was demonstrated in prostate cancer cells by 
Das et al. [49]. Also in a report by Zhu et al. [50], silencing 
of prostatic PC3 cells for AKT resulted in reductions of 
growth promoting RANKL, PTHrP, and BMP-2. Taken 
together, our results suggest that CYP1A1 may act as an 
upstream activator of the PI3K-AKT signaling pathway 
and enhance the transcriptional activation of anti-apoptotic 
genes that include BCL2; and further studies are needed to 
verify this hypothesis.
In summary, we show that CYP1A1 is an important 
oncogene in prostate cancer that is up-regulated by DNA 
promoter hypomethylation. Tobacco smoking can cause 
a further reduction of methylation at the CYP1A1 distal 
enhancer that may lead to carcinogen activation through 
increased CYP1A1 expression. Furthermore, CYP1A1 is 
shown to have its own oncogenic function and promote 
prostate cancer proliferation and survival via dysregulation 
of BCL2. Altogether our findings demonstrate that 
tobacco smoking may contribute to the pathogenesis of 
prostate cancer and that inhibition of CYP1A1 may have 
therapeutic potential.
MATERIALS AND METHODS
Tissue microarray
In total, 102 primary prostate cancer tissues 
composed of 10 specimens from TMA PR804, 36 from 
TMA PR956, and 56 from TMA PR208 (all acquired 
from US Biomax, Rockville, MD) were evaluated. Also, 
14 normal prostate and 70 BPH specimens were included 
in these 3 TMAs. 
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Clinical samples
A total of 176 newly diagnosed prostate cancer 
tissues from radical prostatectomy and 69 pathologically 
proven BPH samples from transurethral resection were 
obtained from a urology tissue bank at the Veterans 
Affairs (VA) Medical Center. The pathological 
background of the prostate cancer patients includes 
Gleason < 4 – 33 cases, Gleason 5 – 33 cases, Gleason 
6 – 31 cases, Gleason 7 – 47 cases and Gleason > 8 – 
32 cases; pT2 – 117 cases, pT3 – 56 cases and pT4 – 
3 cases. The median age (range) of prostate cancer and 
BPH patients were 69 (49–80 years) and 75 (54–87 
years), respectively. Our routine strategy to diagnose 
prostate cancer included serum PSA level, transrectal 
ultrasonography, color Doppler ultrasonography [51] 
and MRI that enabled us to accurately localize prostate 
cancer before radical prostatectomy. A portion of each 
tissue sample was fixed in 10% buffered formalin (pH 
7.0) and embedded in paraffin wax. Sections (5 µm) were 
used for hematoxylin and eosin staining for histological 
evaluation. Another portion of tissue was frozen fresh 
and stored at –80°C until analyzed. Written informed 
consent was obtained from each patient for molecular 
analyses of the resected specimens and this study was 
approved by the Clinical Research Office of the San 
Francisco VA Medical Center and the Institutional 
Review Board of the University of California at San 
Francisco.
Cell lines and reagents
Human prostate cancer cell lines (PC-3, LNCaP, and 
DU145) were purchased from the American Type Culture 
Collection (Manassas, VA). Keratinocyte serum-free 
medium, bovine pituitary extract and human recombinant 
epidermal growth factor were purchased from Invitrogen 
(Carlsbad, CA). RPMI 1640, Opti-minimum essential 
medium and penicillin/streptomycin were obtained from 
the UCSF Cell Culture Facility (San Francisco, CA). 
Fetal bovine serum was a product of Atlanta Biologicals 
(Lawrenceville, GA). All cell lines were cultured in RPMI 
1640 medium supplemented with 10% FBS. Cells were 
maintained in a humidified atmosphere of 5% CO2/95% 
air at 37°C.
Nucleic acid extraction
Genomic DNA from prostate cancer and BPH 
tissue samples were extracted using a DNA extraction 
kit (Qiagen, Valencia, CA). Genomic DNA from 
cell line samples were extracted using DNAzol 
reagent (Life Technologies, San Diego, CA) and total 
RNA was extracted with TRI reagent (Molecular 
Research Center, Cincinnati, OH) according to the 
manufacturer’s instructions. The RNA pellet obtained 
after isopropanol and ethanol precipitation was dried, 
resuspended in RNase-free water, and stored in aliquots 
of 25 μL at −80°C until reverse-transcribed. The 
concentrations of DNA and RNA were determined with 
a spectrophotometer and their integrity was checked by 
gel electrophoresis. 
cDNA preparation and gene quantification
Using 1 μg of RNA, 0.5 μg of oligo-dT primer and 
0.5 units of RNase inhibitor, cDNA was constructed using 
reverse transcriptase (Promega, Madison, WI). The mRNA 
transcript levels of CYP1A1, CD70, MCL1, TNFRSF11B, 
FAS and BCL2 were measured by the 7500 Fast Real-
Time PCR System (Applied BioSystems, Foster City, 
CA) with GAPDH used as the reference gene. The data 
were analyzed by the delta-delta Ct method to calculate 
the fold-change.
Western blot analysis
Whole cell extracts from cell lines were prepared 
using radio-immunoprecipitation assay buffer (RIPA; 
Thermo Scientific, Rockford, IL) containing protease 
inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). 
Protein quantification was done using a BCA protein assay 
kit (Thermo Scientific) according to the manufacturer’s 
instructions. Total cell protein (15–20 μg) was used for 
Western blotting. Samples were transferred to PVDF 
membranes that were immersed in 3% skim milk 
containing antibody against CYP1A1 (polyclonal #ab3568, 
Abcam, Cambridge, MA), AKT (monoclonal #4691, Cell 
Signaling Technology, Danvers, MA), phospho-AKT 
(monoclonal #4060, Cell Signaling Technology), BCL2 
(polyclonal sc-492, Santa Cruz Biotechnology, Dallas, 
Texas), and GAPDH (monoclonal sc-47724, Santa Cruz 
Biotechnology) overnight at 4°C. Blots were washed 
in TBS containing 0.1% Tween20 and labeled with 
horseradish peroxidase conjugated, secondary anti-rabbit 
antibody (Cell Signaling Technology). Specific complexes 
were visualized with an enhanced chemiluminescence 
detection system (GE Healthcare, Little Chalfont, UK) 
using the Chemidoc imaging system (Bio-Rad, Hercules, 
CA). GAPDH was used as control for equal protein 
loading.
5′-Aza-2-deoxycytidine (5-aza-dC) treatment
Prostate cancer cell lines were treated with 
5-aza-dC (Sigma-Aldrich, St Louis, MO) to screen for 
epigenetic alterations. 5-aza-dC was added to fresh cell 
culture medium at a concentration of 5 µM in duplicate 
wells. The cultured cells were harvested after 4 days of 
treatment. The mRNA transcripts before and after 5-aza-
dC treatment were analyzed by real-time PCR after cDNA 
conversion.
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Bisulfite DNA sequencing and methylation 
analysis
Genomic DNA (100 ng) was modified with sodium 
bisulfite (Sigma-Aldrich) using a commercial kit (Life 
Technologies). In the CYP1A1 promoter, up to 10 high 
affinity binding sites for the AHR complex has been 
identified [52] and are shown in Figure 6A. Based on 
previous findings the methylation of the -1383 bp CpG site 
located within the distal XRE was significantly affected 
by smoking [17, 18] and shown to regulate CYP1A1 
expression [18], and our methylation analysis was focused 
on this CpG site (XRE-1383, region A, Figure 6A). In 
addition, we evaluated region B which contains XRE 
at -983 bp (XRE-983) that also is affected by smoking 
[18] as well as region C that contains XRE at the -895 
bp site (XRE-895, Figure 6A). Universal, methylation-, 
and unmethylation-specific PCR primers were designed 
using a MethPrimer program (http://itsa.ucsf.edu/~urolab/
methprimer) according to our previous studies [12–14]. 
The 3 regions (A, B, and C) amplified by these primers 
have 5, 22 and 13 CpG sites, respectively, and a schematic 
diagram of the location of these primers and CpG sites 
are shown in Figure 6B. For MSP (methylation-specific 
PCR), a second round of nested PCR (MSP and USP 
(unmethylation-specific PCR)) was done using the 
universal PCR product amplified by universal-sense and 
universal-antisense primers as a template. The universal 
primer sets contain no CpG sites in either the forward 
or reverse primer. In each amplification, the absence 
of a DNA template served as a negative control. The 
universal primer sequences for regions A through C were 
5′-GGGATTATTTTTTGGTTTGGATTA-3′ (sense) and 
5′-CATAACCTAACTACCTACCTCC-3′ (antisense), 
5′-AGGTTGGTTTTTTAAGAGTTT-3′ (sense) and 
5′-ATTAACAAAACACAAAAATCC-3′ (antisense), 
and 5′-TTTGTTTTTTAGAGGGATGT-3′ (sense) and 
5′-CTTTAATTAACAAAACACAAAAAT-3′ (antisense), 
respectively. The MSP primer sequences for regions A-C 
were 5′- GGGTTAGGTGAGTTAGGTCG-3′ (sense) and 
5′- CCGACGCTATCCCGCCCTCCG-3′ (antisense), 
5′- CGGGTTTTCGGTTTTTTTTAC-3′ (sense) and 
5′- CCCGACTCTAACTTACGTACG-3′ (antisense), 
and 5′- TAGAGGGATGTCGTCGGCGTAC-3′ (sense) 
and 5′- TAACAAAACACAAAAATCCGACGACG- 
3′ (antisense), respectively. The USP 
primer sequences for regions A-C were 5′- 
TGGGGTTAGGTGAGTTAGGTTG-3′ (sense) and 
5′- TCCAACACTATCCCACCCTCCA-3′ (antisense), 
5′- GTGGGTTTTTGGTTTTTTTTATGT-3′ (sense) and 
5′- CCCCAACTCTAACTTACATACACC-3′ (antisense), 
and 5′- TAGAGGGATGTTGTTGGTGTAT-3′ (sense) 
and 5′- TAACAAAACACAAAAATCCAACAACA- 
3′ (antisense), respectively. The MSP and USP products 
were analyzed by 2% agarose gel electrophoresis. Density 
of each band was calculated by Image J software (http://
rsb.info.nih.gov/ij) and the relative methylation level in 
each sample was determined using the following formula; 
MSP ratio (%) = MSP /[MSP+USP]. DNA sequencing 
was also performed on bisulfite-modified DNA. One µl 
of modified DNA was amplified using a pair of universal 
primers in a total volume of 20 μL. Sequencing of the PCR 
products using either a forward or reverse universal primer 
was done according to the manufacturer’s instructions 
(Applied Biosystems). 
Knockdown of CYP1A1 in LNCaP and DU145 
cells 
siRNA oligonucleotides against human CYP1A1 
and mismatch control oligonucleotides were purchased 
from Life Technologies. For inhibition of CYP1A1, 5 µl 
of siRNA oligonucleotides (siRNA-CYP1A1 (s3800 
(designated #1), s3801 (designated #2), or siRNA-control) 
and 5 µl of lipofectamine RNAiMAX reagent (Life 
Technologies) were diluted with 250 µl of Opti-MEM 
(Gibco, Carlsbad, CA). Cells were then transfected with 
lipofectamine+siRNA-CYP1A1 (#1 or #2) or siRNA-
control. Transfection was terminated after 5 hours by 
aspirating the transfection medium including non-adherent 
cells and adding fresh RPMI 1640 containing 10% FBS. 
The remaining cells were incubated at 37˚C.
MTS assay
Cells were plated in triplicate in 96-well microplates 
at a density of 3 × 103 cells per well. After treatment 
with CYP1A1 siRNA, the number of viable cells was 
determined over time by adding 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium-based CellTiter 96 Aqueous One Solution 
Reagent (Promega) to each well and measuring the 
absorbance at 490 nm on SPECTRA MAX 190 plate 
reader (Molecular Devices, Sunnyvale, CA).
Apoptosis assay
Fluorescence-activated cell-sorting (FACS) analysis 
for apoptosis was done 48 hours post-transfection using 
an annexin V-fluorescein isothiocyanate (FITC)/7-amino-
actinomycin D (7-AAD) staining system obtained from 
BD Biosciences (San Jose, CA) and a BD FACSVerseTM 
flow cytometer (BD Biosciences). Cells were stained with 
annexin V-FITC only (early apoptotic) or both annexin 
V-FITC and 7-AAD (late apoptotic), and the combined 
sum was considered to be the total apoptotic cell fraction.
Apoptosis-related gene array analyses
cDNAs from control and CYP1A1 siRNA#2-treated 
cells were evaluated for gene expression using the RT2 
ProfilerTM PCR Array PAHS-012ZC (Human Apoptosis 
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PCR Array, Qiagen) on the ABI Fast 7500 Real-Time PCR 
System with RT2 Real-Time SYBR Green PCR master 
mix according to the manufacturer’s protocol.
Immunohistochemical analyses
Immunostaining of CYP1A1 was performed on 
TMA (tissue microarray) slides using the UltraVision 
Detection System (Thermo Scientific) according to the 
manufacturer’s instructions. After 12 hours incubation 
with rabbit polyclonal antibody for CYP1A1 (1:200, 
#ab3568, Abcam), 3,3′-diaminobenzidine was added as 
chromogen followed by counterstaining with hematoxylin. 
The degree of immunostaining was evaluated by two 
independent observers. Cytoplasmic expression was 
analyzed by the intensity of positive cells using Image J 
software (http://rsb.info.nih.gov/ij) and was ranked on an 
overall scale from 0 to 3; with 0 indicating the absence 
of staining; 1, weak staining; 2, moderate staining; and 3, 
strong staining according to our previous study [53].
Statistical analyses
Values are presented as the mean ± standard error 
based on results obtained from at least three independent 
experiments. All data were analyzed using StatView 5 
statistical software (SAS Institute, Inc., Cary, NC). The 
relationship between two variables was analyzed using 
the two-tailed unpaired Student’s t-test. Cohen’s d value 
was calculated to determine effect size difference between 
groups. A p-value of less than 0.05 was considered to be 
statistically significant.
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